“The completion of the C-Pulse Heart Assist System feasibility...

“The completion of the C-Pulse Heart Assist System feasibility trial demonstrates that C-Pulse has the potential to help the millions of moderate to severe heart failure patients who have limited, if any, therapeutic interventions available to them,” said Dave Rosa,

That for me was the takeaway line. Add that to the fact it is highly likely that even patients treated with Stem Cell therapy such as being trialled by MSB will still need to use a C-Pulse device as part of their treatment.

All travelling well, looking forward to the Nasdaq listing so we can get some more North American instos on board. They are wasting their time here on the ASX.